Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01363778 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects

A Phase 1 study of Healthy, sponsored by AVEO Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT01363778 is a Phase 1 study of Healthy that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01363778, a Phase 1 study of Healthy, has completed, sponsored by AVEO Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is designed to evaluate the effect ketoconazole on the Pharmacokinetic profile of tivozanib.

Conditions Studied

Interventions

  • DRUG tivozanib

Study Locations (1)

Wisconsin

  • Covance Clinical Research Unit, Inc. - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-05
Est. Completion 2011-07
Phase Phase 1

Sponsor

AVEO Pharmaceuticals

27 total trials

What the Registry Record Tells You About NCT01363778

The ClinicalTrials.gov registry entry for NCT01363778 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which tivozanib is the first listed.

NCT01363778 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01363778 about?

NCT01363778 is a clinical study titled "A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects". This study is designed to evaluate the effect ketoconazole on the Pharmacokinetic profile of tivozanib.

What is the current status of trial NCT01363778?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2011-07.

What conditions does trial NCT01363778 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01363778?

The interventions under investigation include: tivozanib (DRUG).

Who is sponsoring clinical trial NCT01363778?

This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01363778 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.